Pri­vate eq­ui­ty firm taps ex-Ed­i­tas CEO Jim Mullen to help ex­pand phar­ma port­fo­lio — with a nod to cell, gene ther­a­pies

Jim Mullen is lend­ing his years of biotech CEO ex­pe­ri­ence — from Bio­gen, Patheon and Ed­i­tas — to the pri­vate eq­ui­ty firm Ad­vent In­ter­na­tion­al.

Ad­vent man­ag­ing part­ner John Mal­don­a­do said Mullen will help his team ex­pand their reach to phar­ma­ceu­ti­cal and phar­ma ser­vices com­pa­nies “across con­tract man­u­fac­tur­ing, com­mer­cial­iza­tion, and re­search.”

“Jim’s work at Ed­i­tas and Ther­mo Fish­er have put him at the fore­front of the cell and gene ther­a­py rev­o­lu­tion,” Carmine Petrone, man­ag­ing di­rec­tor at Ad­vent, added in a state­ment. “We are ex­cit­ed to part­ner with Jim as we con­tin­ue to look for trans­for­ma­tive com­pa­nies that are en­abling the de­vel­op­ment, man­u­fac­ture and com­mer­cial­iza­tion of these ad­vanced ther­a­pies.”

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN